Carcinoembryonic antigen (CEA) assays (2536) were performed in 380 disease-free breast cancer patients after radical mastectomy. In the 334 evaluable patients with 3 or more determinations, the overall relapse rate after a median follow-up of 29 months was 11 %. Of 203 patients with normal CEA values, 19 (9.3 %) relapsed. In the 50 patients with the highest CEA value greater than 20 ng/ml, the relapse rate was 26 %; in the 12 patients with gradually increasing CEA elevations it was 50 %. However, CEA was unable to predict recurrence in N- patients. Premastectomy N+ was significantly associated with greater than 20 ng/ml or gradually increasing CEA values, suggesting the lack of an independent prognostic value of CEA in our patient population.
Get full access to this article
View all access options for this article.
References
1.
AndersonJ.M., StimsonW.H., GettinbyG., JhunjhunwalaS.K., BurtR.W.: Detection of mammary micrometastases by pregnancy-associated α2-glyco-protein (PAG, α2-PAG or PAM) and carcinoembryonic antigen (CEA).Eur. J. Cancer, 15: 709–714, 1979.
2.
AttiyekF.F., StearnsM.W.Jr.: Second-look laparotomy based on CEA elevations in colorectal cancer.Cancer, 47: 2119–2125, 1981.
3.
Carcinoembryonic antigen: Its role as a marker in the management of cancer.National Institutes of Health consensus development conference statement.Cancer Res., 41: 2017–2018, 1981.
4.
ChatalJ.F., ChupinF., RicolleauG., TellierJ.L., Le MevelA., FumoleauP., GodinO., Le MevelB.P.: Use of serial carcinoembryonic antigen assays in detecting relapses in breast cancer involving high risk of metastases.Eur. J. Cancer, 17: 233–238, 1981.
5.
CoombesR.C., PowlesT.J., GazetJ.C., FordH.T., NashA.G., SloaneJ.P., HylliardC.J., ThomasP., KeyserJ.W., MarcusD., ZinbergN., StimsonW.H., Munro-NevilleA.: A biochemical approach to the staging of human breast cancer.Cancer, 40: 937–944, 1977.
6.
De Jong-BakkerM., HartA.A.M., PersijnJ.P., CletonF.J.: Prognostic significance of CEA in breast cancer: A statistical study.Eur. J. Cancer Clin. Oncol., 17: 1307–1313, 1981.
7.
Dell'AnnaB., PercudaniM., SalvadoriC.: ACE et tumeurs mammaires: Application d'une méthode personnelle de détermination de l'ACE à l'étude clinique de 242 malades.Bull. Cancer (Paris), 66: 259–268, 1979.
8.
DentP.B., McCullochP.B.: Detection of recurrent metastases using tumor associated serum markers: Validity of results.Eur. J. Cancer, 16: 963, 1980.
9.
DoyleP.J., NicholsonR.I., GroomeG.V., BlarneyR.W.: Carcinoembryonic antigen (CEA): Its role as a tumor marker in breast cancer.Clin. Oncol., 7: 53–58, 1981.
10.
FalksonH.C., Vander WattJ.J., PortugalM.A., SchoemanH.S., FalksonG.: Role of plasma carcinoembryonic antigen in evaluating patients with breast cancer treated with adjuvant chemotherapy.Cancer Treat. Rep., 63: 1303–1309, 1979.
11.
FisherB., GebhardtM.C.: The evaluation of breast cancer surgery: Past, present and future.Semin. Oncol., 5: 385–393, 1978.
12.
GentiliC., SanfilippoO., SilvestriniR.: Cell proliferation and its relationship to clinical features and relapse in breast cancers.Cancer, 48: 974–979, 1981.
13.
GoldP., SchusterJ., FreedmanS.O.: Carcinoembryonic antigen (CEA) in clinical medicine.Historical perspectives, pitfalls and projections. Cancer, 42: 1399–1405, 1978.
14.
HaagensenD.E., KisterS.J., VandervoordeJ.P., GatesJ.B., SmartE.K., HansenH.J., WellsS.A.: Evolution of carcinoembryonic antigen as a plasma monitor for human breast carcinoma.Cancer, 42: 1512–1519, 1978.
15.
McGuireW.: Hormone receptors: Their role in predicting prognosis and response to endocrine therapy.Semin. Oncol., 5: 428–433, 1978.
16.
MyersR.E., SutherlandD.J., MeakiniJ.W., KellenI.A., MalkinD.G., MalkinA.: Carcinoembryonic antigen in breast cancer.Cancer, 42: 1520–1526, 1978.
17.
TNM Classification of Malignant Tumours.Geneva: International Union Against Cancer (UICC),3rd ed., 1978.
18.
TubianaM., PejovicM.J., RenaudA., ContessoG., ChavaudraN., GioanniJ., MalaiseE.P.: Kinetic parameters and the course of the disease in breast cancer.Cancer, 47: 937–943, 1981.
19.
WangD.Y., BulbrookR.D., HaywardJ.L., HendrickJ.C., FranchimontP.: Relationship between plasma carcinoembryonic antigen and prognosis in breast cancer.Eur. J. Cancer, 11: 615–618, 1975.
20.
ZamchekN., KupchikN.: Summary of clinical use and limitations of the carcinoembryonic antigen assay and same methodological considerations. In: Manual of Clinical Immunolgy, RoseR., & FriedmanH. Eds., pp. 753–764. Amer. Soc. for Microbiology.Washington D.C., 1976.
